CD19/BCMA CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus - Safety and Preliminary Efficacy Data from a Phase I Clinical Study

被引：19

作者：

Feng, Jingjing ^{[1
]}

Hu, Yongxian ^{[2
]}

Chang, Alex H. ^{[3
,4
]}

Huang, He ^{[5
,6
,7
,8
]}

机构：

[1] Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China

[2] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Sch Med, Hangzhou, Peoples R China

[3] Fudan Univ, Inst Genet, Sch Life Sci, Engn Res Ctr Gene Technol,Minist Educ, Shanghai, Peoples R China

[4] Shanghai YaKe Biotechnol Ltd, Shanghai, Peoples R China

[5] Zhejiang Univ, Liangzhu Lab, Med Ctr, Hangzhou, Peoples R China

[6] Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, Hangzhou, Peoples R China

[7] Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China

[8] Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Peoples R China

来源：

关键词：

D O I：

10.1182/blood-2023-186669

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3